1. Scrip
  2. >>Business
  3. >>Financing

Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0

Serial Entrepreneur Gary Glick Previously Founded IFM, Lycera, FirstWave

 
• By Mandy Jackson

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
Scorpion closed a $108m series A round to fund precision oncology drugs • Source: Shutterstock

Gary Glick’s fourth biotechnology firm, Scorpion Therapeutics, emerged from stealth mode on 26 October with $108m to develop small molecules that are safer, more tolerable and provide deeper, more durable responses to treatment than current targeted cancer therapies. The start-up believes that it has assembled a drug discovery engine on par with big pharma capabilities.

Scrip spoke with Scorpion co-founder and CEO Glick, who previously founded IFM Therapeutics, Lycera Corporation and FirstWave Bio, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business